<DOC>
	<DOCNO>NCT02246712</DOCNO>
	<brief_summary>This study aim investigate influence uncontrolled type 1 type 2 diabetes mellitus ( DM ) kinetic disposition , metabolism pharmacokinetics-pharmacodynamics tramadol enantiomer patient neuropathic pain . Thus , nondiabetic patient ( control group , n = 12 ) , patient type 1 DM ( n = 9 ) , patient type 2 DM ( n = 9 ) , neuropathic pain phenotyped extensive metabolizers cytochrome P450 2D6 ( CYP2D6 ) treat single oral dose 100 mg racemic tramadol investigate .</brief_summary>
	<brief_title>Influence Diabetes Tramadol Pharmacokinetics</brief_title>
	<detailed_description>Tramadol centrally act analgesic effectively relieve acute chronic pain , include neuropathic pain diabetic patient . The drug available clinical practice mixture ( + ) -tramadol ( - ) -tramadol enantiomer . Tramadol metabolize CYP2D6 O-desmethyltramadol ( M1 ) cytochrome P450 3A ( CYP3A4 ) cytochrome P450 2B6 ( CYP2B6 ) N-desmethyltramadol ( M2 ) . Both tramadol enantiomer ( + ) -M1 contribute analgesic activity drug : ( + ) -tramadol ( + ) -M1 metabolite act -opioid receptor agonist ; ( + ) -tramadol inhibits serotonin reuptake ; ( - ) -tramadol inhibits reuptake norepinephrine . This study investigate influence uncontrolled type 1 type 2 diabetes mellitus ( DM ) kinetic disposition , metabolism pharmacokinetics-pharmacodynamics tramadol enantiomer patient neuropathic pain . Nondiabetic patient ( control group , n = 12 ) , patient type 1 DM ( n = 9 ) , patient type 2 DM ( n = 9 ) , neuropathic pain phenotyped extensive metabolizers CYP2D6 , receive single oral dose 100 mg racemic tramadol . Serial blood sample collect 24 h administration drug pharmacokinetic study analysis noradrenaline plasma . Pain rat visual analog pain scale time blood sampling . The patient evaluate vivo CYP3A activity use midazolam probe drug genotyped CYP2B6 . Total unbound plasma concentration tramadol , M1 M2 enantiomer analyze liquid chromatography couple tandem mass spectrometry ( LC-MS/MS ) .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<mesh_term>Tramadol</mesh_term>
	<criteria>Adult patient , gender Patients selfreported neuropathic pain ( score &gt; 4 010 visual analog scale ) Patients normal renal function ( creatinine clearance &gt; 60 mL/min ) Patients nociceptive somatic pain , visceral autonomic associate study period ; Patients morbid obesity ( BMI &gt; 40 ) , congestive heart failure , severe hypertension Patients acute myocardial infarction accident stroke less 6 month period investigation . Patients chronic obstructive pulmonary disease Patients use analgesic , CYP2D6 inhibitor CYP3A4 inducer inhibitor exclude . Pregnant lactate patient exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>tramadol</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>enantiomer</keyword>
	<keyword>metabolism</keyword>
	<keyword>diabetes</keyword>
</DOC>